Form 4: Arcutis Biotherapeutics CFO Latha Vairavan Reports Stock and Option Awards

Latha Vairavan, CFO of Arcutis Biotherapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• Latha Vairavan, the SVP and Chief Financial Officer of Arcutis Biotherapeutics, Inc. [ARQT], filed a Form 4 on May 7, 2025.
• The report details transactions from May 6, 2025, where Vairavan acquired 20,000 shares of common stock in the form of Restricted Stock Units (RSUs) and options to purchase 60,000 shares of common stock.
• The RSUs will vest as to 25% on each annual anniversary of May 1, 2025, starting May 1, 2026, contingent upon continued service.
• The stock options vest in 1/48th increments monthly, starting May 6, 2025, also subject to continued service, and expire on May 6, 2035.
• Following these transactions, Vairavan beneficially owns 65,104 shares of common stock and options for 60,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a common practice and generally viewed as a positive sign, aligning management's interests with shareholders. There are no red flags or negative information in the document.

Positives

• The granting of RSUs and stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
• The vesting schedules for both the RSUs and stock options encourage long-term commitment from the CFO.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules suggest an expectation of continued service from the CFO.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent.
• Vesting schedules, such as the ones described in the document, are standard practice to ensure long-term alignment between executives and shareholders.
• Comparing the size of the grant to those of CFOs at similarly sized biotech companies (e.g., companies with similar market capitalization and revenue) would provide further context on the competitiveness of the compensation package.

Stakeholder Impact

• Shareholders may view the stock and option awards as a positive sign, indicating that the CFO is incentivized to increase shareholder value.
• Employees may see the awards as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Form 4, Arcutis Biotherapeutics, ARQT, Latha Vairavan, CFO, Restricted Stock Units, Stock Options, Beneficial Ownership, Vesting